Form 4: AN2 Therapeutics Director Stephanie Wong Acquires Stock Options

Director Stephanie Wong of AN2 Therapeutics, Inc. reports the acquisition of stock options.

Summary

• On June 19, 2024, Stephanie Wong, a director of AN2 Therapeutics, Inc., acquired stock options for 64,503 shares.
• The exercise price of these options is $2 per share.
• The options vest on the earlier of June 19, 2025, or the day before the next annual stockholder meeting, contingent upon continuous service.
• A Power of Attorney was executed on December 13, 2023, granting certain individuals the authority to act on behalf of Stephanie Wong in matters related to SEC filings.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of options could be seen as mildly positive, indicating confidence, but it's a routine filing.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the options is contingent upon continuous service, suggesting an expectation of ongoing involvement from the director.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders and their holdings of company stock.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry, used to align the interests of directors with those of shareholders.
• The vesting schedule and exercise price are typical for such grants, often tied to continued service and market value at the time of the grant.
• Companies like Amgen, Gilead Sciences, and Biogen also regularly grant stock options to their directors as part of their compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director can potentially align the director's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates